Cargando…
Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment
Type 1 insulin like growth factor receptor (IGF-1R) targeted therapies showed compelling pre-clinical evidence; however, to date, this has failed to translate into patient benefit in Phase 2/3 trials in unselected patients. This was further complicated by the toxicity, including hyperglycemia, which...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495315/ https://www.ncbi.nlm.nih.gov/pubmed/26217584 http://dx.doi.org/10.3389/fonc.2015.00142 |